Currently, there are 146.39M common shares owned by the public and among those 136.40M shares have been available to trade.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, accounting for 1,250,000 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 128,501 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 14.56, down -8.23%. The company’s stock has a 5-day price change of -9.25% and 36.30% over the past three months. TGTX shares are trading -18.44% year to date (YTD), with the 12-month market performance down to -22.18% lower. It has a 12-month low price of $6.46 and touched a high of $35.67 over the same period. TGTX has an average intraday trading volume of 0.93 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.63%, -15.19%, and -16.79% respectively.
Institutional ownership of TG Therapeutics Inc (NASDAQ: TGTX) shares accounts for 58.19% of the company’s 146.39M shares outstanding.
It has a market capitalization of $2.11B and a beta (3y monthly) value of 2.32. The earnings-per-share (ttm) stands at -$0.27. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.08% over the week and 5.20% over the month.
Earnings per share for the fiscal year are expected to increase by 98.97%, and -782.68% over the next financial year.
Looking at the support for the TGTX, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on August 02, 2023, with the firm’s price target at $16-$12.
